Pulmonx Corporation (NASDAQ:LUNG) Short Interest Update
by Doug Wharley · The Cerbat GemPulmonx Corporation (NASDAQ:LUNG – Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 3,086,595 shares, a growth of 22.2% from the November 30th total of 2,526,582 shares. Currently, 8.0% of the company’s shares are short sold. Based on an average daily trading volume, of 1,189,881 shares, the short-interest ratio is presently 2.6 days. Based on an average daily trading volume, of 1,189,881 shares, the short-interest ratio is presently 2.6 days. Currently, 8.0% of the company’s shares are short sold.
Analyst Ratings Changes
Several equities analysts have weighed in on LUNG shares. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Wednesday, October 8th. D. Boral Capital reiterated a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, November 13th. Finally, Lake Street Capital cut their price target on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pulmonx currently has an average rating of “Hold” and an average price target of $6.81.
Check Out Our Latest Stock Analysis on LUNG
Institutional Trading of Pulmonx
A number of hedge funds have recently added to or reduced their stakes in LUNG. Parkman Healthcare Partners LLC lifted its stake in shares of Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock worth $4,118,000 after acquiring an additional 404,022 shares during the period. Trexquant Investment LP boosted its position in shares of Pulmonx by 140.0% in the 1st quarter. Trexquant Investment LP now owns 224,909 shares of the company’s stock worth $1,514,000 after buying an additional 131,209 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Pulmonx by 32.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock valued at $567,000 after acquiring an additional 53,148 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in Pulmonx in the 2nd quarter valued at about $197,000. Finally, R Squared Ltd purchased a new stake in shares of Pulmonx in the second quarter valued at about $41,000. 91.04% of the stock is owned by institutional investors and hedge funds.
Pulmonx Stock Performance
Shares of LUNG stock traded down $0.07 during mid-day trading on Wednesday, hitting $2.21. 482,764 shares of the stock were exchanged, compared to its average volume of 873,781. The stock has a market capitalization of $91.16 million, a price-to-earnings ratio of -1.57 and a beta of 0.22. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37. The stock’s fifty day simple moving average is $1.96 and its two-hundred day simple moving average is $2.04. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86.
Pulmonx (NASDAQ:LUNG – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The business had revenue of $21.50 million during the quarter, compared to the consensus estimate of $20.78 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. On average, analysts forecast that Pulmonx will post -1.55 EPS for the current year.
About Pulmonx
Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.
The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.